Skip to main content
. Author manuscript; available in PMC: 2022 Mar 11.
Published in final edited form as: Int J Cancer. 2021 Jun 10;149(6):1302–1312. doi: 10.1002/ijc.33702

Table 2.

Associations of three significant SNPs with of NSCLC overall survival in both discovery and validation datasets from two published GWASs

SNPs Allelea Gene PLCO (n=1,185)
 HLCS (n=984)
 Meta-analysis
EAF HR (95% CI)b P b EAF HR (95% CI)C P C P hetd I 2 HR (95% CI)e P e
rs76744140 T>C CHEK1 0.07 1.28 (1.06–1.55) 0.010 0.05 1.30 (1.02–1.64) 0.033 0.920 0 1.29 (1.11–1.49) 8.26x10−4
rs6939623 G>T PRIM2 0.09 1.34 (1.13–1.58) 0.001 0.09 1.19 (1.01–1.40) 0.039 0.324 0 1.26 (1.12–1.42) 1.10x10−4
rs113181986 G>C CDK6 0.06 0.75 (0.59–0.94) 0.014 0.07 0.72 (0.58–0.90) 0.004 0.804 0 0.73 (0.63–0.86) 1.63x10−4

Abbreviations: SNPs, single-nucleotide polymorphisms; NSCLC, non-small cell lung cancer; GWAS, genome-wide association study; PLCO, the Prostate, Lung, Colorectal and Ovarian cancer screening trial; HLCS, Harvard Lung Cancer Susceptibility Study; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval.

a

Reference/effect allele.

b

Adjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, identified SNPs, PC1, PC2, PC3 and PC4.

c

Adjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2 and PC3.

d

Phet: P value for heterogeneity by Cochrane’s Q test.

e

Meta-analysis in the fix-effects model.